Safety for Home Administration of Microdose Psilocybin Use

This single-blind interventional trial (n=20) will investigate the safety of ascending doses of psilocybin for home administration.

The study is designed to assess whether different microdoses of psilocybin (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg) can be safely administered at home. Participants will receive these doses, as well as a single placebo, on separate days. They will undergo a series of safety assessments and complete questionnaires at each dosing session.

The trial, conducted by Johns Hopkins University and funded by private philanthropic funds, aims to identify safe dosages for at-home use and evaluate their potential impact on participants’ health.

The study began in August 2024 and is expected to conclude in June 2027.

Trial Details

The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in single-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.

NCT Number NCT06450210

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.